Evaluation of immunohistochemical staining with PMab-38, an anti-dog podoplanin monoclonal antibody, in various canine tumor tissues

Kohei Kiname, Sho Yoshimoto, Daiki Kato, Masaya Tsuboi, Yuiko Tanaka, Ryohei Yoshitake, Shotaro Eto, Masahiro Shinada, James Chambers, Kohei Saeki, Ryohei Kinoshita, Shinji Yamada, Kazuyuki Uchida, Mika K. Kaneko, Ryohei Nishimura, Yukinari Kato, Takayuki Nakagawa

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Podoplanin (PDPN) is a type I transmembrane sialoglycoprotein with O-glycosylation and a high content of sialic acid. PDPN has been reported to be expressed in various human tumors and promote tumor progression, epithelial-mesenchymal transition, and distant metastasis. PDPN is also expressed in cancer-associated fibroblasts (CAFs), which promote tumor growth. We have developed novel tumor specific anti-PDPN antibodies. PMab-38, which is an anti-dog PDPN monoclonal antibody, recognized PDPN expression in canine squamous cell carcinoma (SCC) and malignant melanoma. However, there has been no research into PMab-38 recognition of other types of tumors and systemic normal tissue. The objective of this study was to evaluate the staining positivity of PMab-38 by immunohistochemical staining of various paraffin-embedded canine tumor and systemic normal tissues. Immunohistochemical analysis revealed that PMab-38 positively stained tumor cells in 9/11 (82%) SCC and 9/11 (82%) pulmonary adenocarcinoma tissues. In the tumor stroma, large spindle-shaped mesenchymal cells, which were suspected to be CAFs, were stained by PMab-38 in almost all tumor types: 9/10 (90%) for anal sac adenocarcinoma and 11/12 (92%) for transitional cell carcinoma tissues. Almost all normal tissues were negatively stained with PMab-38 except part of the kidney glomerulus. Taken together, our findings provide evidence that various types of tumor cells were strongly stained by PMab-38, but most normal cells were not stained. These results indicate that PDPN recognized by PMab-38 might be a target for tumor antigen targeting therapy. Further studies are required to investigate the antitumor effect in various canine tumors by antibody therapy using PMab-38.

Original languageEnglish
Pages (from-to)25-34
Number of pages10
JournalJapanese Journal of Veterinary Research
Issue number1
Publication statusPublished - 2019


  • Canine cancer
  • Pmab-38
  • Podoplanin


Dive into the research topics of 'Evaluation of immunohistochemical staining with PMab-38, an anti-dog podoplanin monoclonal antibody, in various canine tumor tissues'. Together they form a unique fingerprint.

Cite this